Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Type 2 diabetes: pathogenesis and treatment.

Stumvoll M, Goldstein BJ, van Haeften TW.

Lancet. 2008 Jun 28;371(9631):2153-6. doi: 10.1016/S0140-6736(08)60932-0. No abstract available.

PMID:
18586159
2.

Extended-release exenatide (Bydureon) for type 2 diabetes.

[No authors listed]

Med Lett Drugs Ther. 2012 Mar 19;54(1386):21-3. No abstract available.

PMID:
22421818
3.

[GLP-1 receptor agonists: an effective wide-spectrum therapeutic approach in the treatment of type 2 diabetes mellitus].

Salvador J, Gaztambide S.

Med Clin (Barc). 2014 Sep;143 Suppl 2:1. doi: 10.1016/S0025-7753(14)70100-9. Spanish. No abstract available.

PMID:
25437457
4.

[Beyond glycemic control in type 2 diabetes. Promises and gambles of therapy with glucagon-like peptide-1 receptor agonists].

Mannucci E.

G Ital Cardiol (Rome). 2011 Dec;12(12 Suppl 2):3-4. doi: 10.1714/985.10683. Italian. No abstract available.

PMID:
22158420
5.

Integrating incretin-based therapy into type 2 diabetes management.

Brunton SA.

J Fam Pract. 2013 Jun;62(6 Suppl CME):S1-8. No abstract available.

PMID:
23828807
6.

GLP-1 receptor agonists and basal insulin in type 2 diabetes.

Young LA, Buse JB.

Lancet. 2014 Dec 20;384(9961):2180-1. doi: 10.1016/S0140-6736(14)61409-4. No abstract available.

PMID:
25220193
7.

Type 2 diabetes: epidemiology and treatment, pathophysiology, new therapeutics, and the evolving role of the pharmacist.

Campbell RK, Neumiller JJ, White J, Sisson E, Kuhn C.

J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S2. doi: 10.1331/JAPhA.2009.09537. No abstract available.

PMID:
19801362
8.

Evidence-based practice use of incretin-based therapy in the natural history of diabetes.

Schwartz S.

Postgrad Med. 2014 May;126(3):66-84. doi: 10.3810/pgm.2014.05.2757. Review.

PMID:
24918793
9.

Glucagon-like peptide-1 receptor agonists vs. insulin in inadequately controlled patients with type 2 diabetes. Is this meta-analysis miscalculated?

Liatis S, Makrilakis K.

Diabetes Obes Metab. 2014 Mar;16(3):284. doi: 10.1111/dom.12213. No abstract available.

PMID:
24495116
10.

Liraglutide (Victoza) for type 2 diabetes.

[No authors listed]

Med Lett Drugs Ther. 2010 Apr 5;52(1335):25-7.

PMID:
20360660
11.

Review: in type 2 diabetes, GLP-1 agonists plus basal insulin reduce HbA1c without increasing hypoglycemia.

Ospina NS, Montori VM.

Ann Intern Med. 2015 Jan 20;162(2):JC6. doi: 10.7326/ACPJC-2015-162-2-006. No abstract available.

PMID:
25599366
12.

[Therapeutic indications of incretin-related derivatives and other oral hypoglycemic agents].

Katsuno T, Miyagawa J.

Nihon Rinsho. 2012 May;70 Suppl 3:693-8. Japanese. No abstract available.

PMID:
22768600
13.

Glucagon-like peptide-1 receptor agonists for diabetes mellitus: a role in cardiovascular disease.

Smilowitz NR, Donnino R, Schwartzbard A.

Circulation. 2014 Jun 3;129(22):2305-12. doi: 10.1161/CIRCULATIONAHA.113.006985. Review. No abstract available.

14.

[Glucagon-like peptide-1 receptor agonists].

Kurose T, Seino Y.

Nihon Rinsho. 2012 May;70 Suppl 3:689-92. Japanese. No abstract available.

PMID:
22768599
15.

Incorporating glucagon-like peptide-1 receptor agonists into clinical practice.

Spellman CW.

J Am Osteopath Assoc. 2012 Jan;112(1 Suppl 1):S7-15. Review.

PMID:
22267302
16.

Can GLP-1 preparations be used in children and adolescents with diabetes mellitus?

Shehadeh N, Daich E, Zuckerman-Levin N.

Pediatr Endocrinol Rev. 2014 Mar;11(3):324-7. Review.

PMID:
24716398
17.

[DPP-4 inhibitors, GLP-1 receptor agonists].

Hamasaki A, Inagaki N.

Nihon Rinsho. 2011 Jan;69 Suppl 1:654-61. Review. Japanese. No abstract available.

PMID:
21766677
18.

Glucagon-like peptide-1 and diabetes 2012.

Monami M, Di Pasquale G, Rowzee A, Rotella CM, Mannucci E.

Exp Diabetes Res. 2012;2012:768760. doi: 10.1155/2012/768760. No abstract available.

19.

Individualizing care with injectable glucose-lowering agents.

Miller EM.

J Fam Pract. 2013 Dec;62(12 Suppl CME):S12-9.

PMID:
24340344
20.

[When injectable diabetes therapy becomes necessary. Insulin or GLP-1 analogs?].

Stiefelhagen P.

MMW Fortschr Med. 2011 Jan 13;153(1-2):14. German. No abstract available.

PMID:
24761480
Items per page

Supplemental Content

Support Center